PURE Bioscience, Inc. PURE
OTC PK
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 30.43% | 13.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30.43% | 13.96% | |||
| Cost of Revenue | 22.78% | 15.05% | |||
| Gross Profit | 37.17% | 13.03% | |||
| SG&A Expenses | 10.03% | -16.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.57% | -9.14% | |||
| Operating Income | 2.90% | 24.16% | |||
| Income Before Tax | 2.24% | 20.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.24% | 20.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.24% | 20.51% | |||
| EBIT | 2.90% | 24.16% | |||
| EBITDA | 3.09% | 24.05% | |||
| EPS Basic | 17.86% | 20.00% | |||
| Normalized Basic EPS | 17.14% | 20.45% | |||
| EPS Diluted | 17.86% | 20.00% | |||
| Normalized Diluted EPS | 17.14% | 20.45% | |||
| Average Basic Shares Outstanding | 18.37% | -0.94% | |||
| Average Diluted Shares Outstanding | 18.37% | -0.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||